Two developments this week point toward a longer view of GLP-1 medications, one that goes beyond weight loss and into chronic disease treatment. Novo Nordisk is testing semaglutide against a serious liver condition, in a trial that will take five years to complete. A new oral GLP-1 pill has also finished the last stage of its studies, though it is not yet approved. For patients watching this class of drugs evolve, both signal that the next phase of GLP-1 medicine is still years away.
NASH, or non-alcoholic steatohepatitis, is a form of liver disease that can progress to scarring and, in some cases, liver failure. There is currently no GLP-1 drug approved specifically to treat it, which means insurance coverage for semaglutide has focused almost entirely on weight and diabetes management. A five-year trial is long by pharmaceutical standards, and it reflects how carefully regulators and drug makers are trying to document safety and effectiveness for a new use of this class of drugs. If the trial succeeds, it could open a path for semaglutide to be prescribed and covered for liver disease on its own terms, separate from any weight loss benefit. That would matter most to patients whose NASH diagnosis exists independent of an obesity diagnosis.
Orforglipron is designed to work similarly to injectable GLP-1 drugs but as a daily pill, which could make it easier for some patients to take consistently and avoid needles altogether. Finishing a final Phase 3 trial is a significant step, since it means the drug maker now has the data needed to submit for FDA approval. That approval process still takes time, and until the FDA grants it, orforglipron cannot legally be prescribed or sold in the United States. Patients interested in this pill should know that completed trials do not guarantee approval, and there is no set date for when the FDA will make a decision. Anyone currently managing obesity or type 2 diabetes with an injectable GLP-1 should not expect this pill as an option in the near term.
For patients following GLP-1 developments, the practical takeaway is that timelines matter as much as headlines. A five-year trial and a completed but unapproved pill both represent progress, but neither changes what is available to prescribe or cover today. If you have NASH, ask your doctor whether current treatment options address your specific diagnosis, since semaglutide is not yet approved for that use. If you are considering a pill form of GLP-1 therapy, plan around what is approved now rather than what might be approved later, and check back for updates as these trials move toward decision points at the FDA.
Key details
Novo Nordisk is running a 5-year trial testing semaglutide for NASH liver disease.
Orforglipron, a daily GLP-1 pill, finished its final trial but remains unapproved.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-09-03
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.